stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) EPS (diluted)
Cytokinetics, Incorporated's EPS (diluted) for fiscal 2025 was −$6.54, compared with −$5.26 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$6.04. Over the past ten years it has ranged from −$6.54 (fiscal 2025) to $0.39 (fiscal 2016) — the current reading is the lowest in ten years. Cytokinetics, Incorporated ranks 462nd of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$6.54 | — |
| FY2024 | −$5.26 | — |
| FY2023 | −$5.45 | — |
| FY2022 | −$4.33 | — |
| FY2021 | −$2.80 | — |
| FY2020 | −$1.97 | — |
| FY2019 | −$2.11 | — |
| FY2018 | −$1.95 | — |
| FY2017 | −$2.59 | — |
| FY2016 | $0.39 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$1.37 | — |
| Jun 2026 | −$1.50 | — |
| Mar 2026 | −$1.67 | — |
| Dec 2025 | −$1.50 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| CORT Corcept Therapeutics Incorporated compare | $1.29 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$2.25 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CYTK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement